Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0EM4S
|
|||
| Former ID |
DNCL001608
|
|||
| Drug Name |
JNJ-39439335
|
|||
| Synonyms |
Mavatrep; 956274-94-5; JNJ-39439335; UNII-F197218T99; F197218T99; Mavatrep [USAN:INN]; Mavatrep (USAN); JNJ 39439335; SCHEMBL1796599; SCHEMBL1797450; CHEMBL2364618; Mavatrep(JNJ-39439335); Mavatrep; JNJ-39439335; DTXSID90241905; BCP23936; EX-A2266; ZINC43175494; BDBM50086717; AKOS030527038; DB12875; CS-4591; SB17026; trans-2-(2-(2-(2-(4-Trifluoromethylphenyl)vinyl)-1H-benzimidazol-5-yl)phenyl)propan-2-ol; BC600772; HY-16935; B5930; J3.561.747G; D10370
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Musculoskeletal pain [ICD-11: MG30; ICD-10: R07.3; ICD-9: 338,780] | Phase 1 | [1] | |
| Company |
Johnson & Johnson Pharmaceutical Research & Development
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H21F3N2O
|
|||
| Canonical SMILES |
CC(C)(C1=CC=CC=C1C2=CC3=C(C=C2)N=C(N3)C=CC4=CC=C(C=C4)C(F)(F)F)O
|
|||
| InChI |
1S/C25H21F3N2O/c1-24(2,31)20-6-4-3-5-19(20)17-10-13-21-22(15-17)30-23(29-21)14-9-16-7-11-18(12-8-16)25(26,27)28/h3-15,31H,1-2H3,(H,29,30)/b14-9+
|
|||
| InChIKey |
ORDHXXHTBUZRCN-NTEUORMPSA-N
|
|||
| CAS Number |
CAS 956274-94-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Transient receptor potential cation channel V1 (TRPV1) | Target Info | Antagonist | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Inflammatory mediator regulation of TRP channels | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | Trk receptor signaling mediated by the MAPK pathway | |||
| Trk receptor signaling mediated by PI3K and PLC-gamma | ||||
| Reactome | TRP channels | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01631487) A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39439335 in Healthy Japanese and Caucasian Adult Male Participants. U.S. National Institutes of Health. | |||
| REF 2 | Benzo[d]imidazole Transient Receptor Potential Vanilloid 1 Antagonists for the Treatment of Pain: Discovery of trans-2-(2-{2-[2-(4-Trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Mavatrep). J Med Chem. 2015 May 14;58(9):3859-74. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.